Reversibility of Ischemia Evaluated by Ischemic Duration and Residual Cerebral Blood Flow

Abstract

We first investigated the time course of CBF thresholds of ischemic cortices by a retrospective review of 19 patients with MCA occlusion who had clearly defined ischemic duration from onset to angiographic complete recanalization. Secondly, CBF thresholds of ischemic cortices salvageable with intravenous low dose native t-PA infusion therapy (7.2 mg of tisokinase) were examined by a retrospective review of 20 patients with distal embolic occlusions of MCA divisions or branches. All patients underwent pretreatment CBF measurement by SPECT using 99mTc-ECD. Pretreatment SPECT and 3 months post-treatment CT images were compared using computerized coregistration. The degree of hypoperfusion was analyzed by an asymmetry index (AI), which was a count-density ratio for the ischemic lesion to the contralateral corresponding area. Ischemic cortices on SPECT were divided into reversible and irreversible lesions.

Judging from the regression lines with 95% confidence interval between the ischemic duration and AI, the infarcted CBF thresholds at 3 and 6 hours after onset may be about 30 and 50% of contralateral presumed normal CBF, respectively.

On the other hand, to save the ischemic tissue with our intravenous t-PA infusion therapy, residual CBF might be needed at least 45% of contralateral presumed normal CBF. It is likely that CBF threshold of ischemia surely salvageable with our intravenous t-PA infusion therapy may be approximately 50–55% of contralateral presumed normal CBF.

Keywords

cerebral ischemia reversibility ischemic duration cerebral blood flow

Get full access to this article

View all access options for this article.

References

Brott

Haley

Jr : Urgent therapy for stroke, part I: Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23: 632–640, 1992.

Haley

Jr Levy

: Urgent therapy for stroke, part II: Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 23: 641–645, 1992.

The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581–1587, 1995.

Hacke

Kaste

. for the ECASS Study Group: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 274: 1017–1025, 1995.

Baron

von Kummer

del Zoppo

: Treatment of acute ischemic stroke: Challenging the concept of a rigid and universal time window. Stroke 26: 2219–2221, 1995.

Hacke

Kaste

, for the Second European-Australasian Acute Stroke Study Investigators: Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 352: 1245–1251, 1998.

Nakano

Yokogami

: Direct percutaneous transluminal angioplasty for acute middle cerebral artery occlusion. Am J Neuroradiol 19: 767–772, 1998.

Nakano

Iseda

: Intravenous low dose native tissue plasminogen activator for distal embolism in the middle cerebral artery divisions or branches: A pilot study. Neurosurgery, in press.

Hossmann

: Viability thresholds and the penumbra of focal ischemia. Ann Neurol 36: 557–565, 1994.

10.

Jones

Morawetz

: Thresholds of focal ischemia in awake monkeys. J Neurosurg 54: 773–782, 1981.

11.

Heiss

Rosner

: Functional recovery of cortical neurons as related to degree and duration of ischemia. Ann Neurol 14: 294–301, 1983.

12.

Marcoux

Morawetz

: Differential regional vulnerability in transient focal cerebral ischemia. Stroke 13: 339–346, 1982.

13.

Nakano

Kinoshita

: Critical cerebral blood flow thresholds studied by SPECT using xenon-133 and iodine-123 iodoamphetamine. J Nucl Med 30: 337–342, 1989.

14.

Ueda

Sakaki

: Outcome in acute stroke with successful intra-arterial thrombolysis and predictive value of initial single-photon emission-computed tomography. J Cereb Blood Flow Metab 19: 99–108, 1999.